Miyakoshi Akinori, Nakatani Eiji, Kaneda Hideaki, Hawke Philip, Sasaki Hatoko, Urano Tetsumei, Miyachi Yoshiki
Shizuoka Graduate University of Public Health, Shizuoka , Japan.
Department of Neurosurgery, Shizuoka General Hospital, Shizuoka , Japan.
Neurosurgery. 2023 Nov 1;93(5):1160-1167. doi: 10.1227/neu.0000000000002558. Epub 2023 Jun 8.
Although tranexamic acid (TXA) has occasionally been used to prevent postoperative recurrence of chronic subdural hematoma (CSDH) after burr hole craniotomy (BC), robust evidence of its efficacy has been lacking.
To assess the efficacy and safety of postoperative oral administration of TXA after BC for CSDH among the elderly.
This retrospective, propensity score-matched cohort study was carried out with a large Japanese local population-based longitudinal cohort in the Shizuoka Kokuho Database between April 2012 and September 2020. Patients included were age 60 years or older and had undergone BC for CSDH but were not undergoing dialysis. Covariates were collected from records of the preceding 12 months from the month of first BC, and patients were followed up for 6 months after surgery. The primary outcome was repeat surgery, and the secondary outcome was death or the onset of thrombosis. Data on postoperative TXA administration were collected and compared with controls using propensity score matching.
Of the 8544 patients who underwent BC for CSDH, 6647 were included, with 473 placed in the TXA group and 6174 placed in the control group. After 1:1 matching, repeated BC was found to have been performed in 30 of 465 patients (6.5%) in the TXA group and in 78 of 465 patients (16.8%) in the control group (relative risk, 0.38; 95% CI, 0.26-0.56). No significant difference was observed for death or the onset of thrombosis.
Oral administration of TXA reduced the occurrence of repeat surgery after BC for CSDH.
尽管氨甲环酸(TXA)偶尔被用于预防钻孔开颅术(BC)后慢性硬膜下血肿(CSDH)的术后复发,但一直缺乏其疗效的确凿证据。
评估老年患者BC治疗CSDH后口服TXA的疗效和安全性。
本回顾性、倾向评分匹配队列研究使用了静冈国保数据库中一个基于日本当地大人群的纵向队列,研究时间为2012年4月至2020年9月。纳入的患者年龄在60岁及以上,因CSDH接受了BC治疗,但未接受透析。协变量从首次BC手术月份前12个月的记录中收集,患者术后随访6个月。主要结局是再次手术,次要结局是死亡或血栓形成。收集术后TXA给药的数据,并使用倾向评分匹配与对照组进行比较。
在8544例因CSDH接受BC治疗的患者中,6647例被纳入研究,其中473例被分入TXA组,6174例被分入对照组。1:1匹配后,TXA组465例患者中有30例(6.5%)进行了再次BC手术,对照组465例患者中有78例(16.8%)进行了再次BC手术(相对风险,0.38;95%CI,0.26 - 0.56)。在死亡或血栓形成方面未观察到显著差异。
口服TXA可降低BC治疗CSDH后再次手术的发生率。